TS
PTCT icon

Thomas Steyer’s PTC Therapeutics PTCT Stock Holding History

Thomas Steyer’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-726,986
Closed -$34.9M – 112
2019
Q4 		$34.9M Hold
726,986
– – 0.24% 66
2019
Q3 		$24.6M Buy
726,986
+126,986
+21% +$5.53M 0.19% 66
2019
Q2 		$27M Sell
600,000
-100,000
-14% -$3.95M 0.18% 68
2019
Q1 		$26.3M Hold
700,000
– – 0.2% 62
2018
Q4 		$24M Buy
700,000
+280,000
+67% +$10.1M 0.18% 62
2018
Q3 		$19.7M Buy
+420,000
New +$17.4M 0.12% 66

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Thomas Steyer's PTCT Position: Q1 2020 in Review

Thomas Steyer sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 726,986 shares — an estimated $34.9M sold.

Thomas Steyer first reported a position in PTCT in Q3 2018 and held it in 6 quarters. The position peaked at $34.9M in Q4 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

  • Thomas Steyer reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Thomas Steyer sold 726,986 PTC Therapeutics shares in Q1 2020, an estimated $34.9M.
  • Thomas Steyer first reported a position in PTC Therapeutics in Q3 2018 and held it in 6 quarters.
  • Thomas Steyer's PTC Therapeutics position peaked at $34.9M in Q4 2019.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.